newsfilter
← Latest News
PR Newswire·

Curis Provides Second Quarter 2024 Financial and Operating Update

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4...